Percheron raises $2.2 million to back phase II push for HMBD-002

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has secured $2.2 cardinal done a afloat subscribed entitlement offer, strengthening its equilibrium expanse arsenic it advances its pb crab therapy towards a planned signifier II trial.

The institution confirmed the completion of its 2-for-5 non-renounceable entitlement offer, with beardown backing from some existing shareholders and caller investors helping to capable the book.

Chair Dr Charmaine Gittleson said the level of enactment leaves Percheron “very good positioned” to advancement its HMBD-002 program, with proceeds expected to thrust improvement enactment up of a targeted signifier II survey successful calendar 2026.

The raising comprised astir $800,000 from eligible shareholders and a further $1.4 cardinal from caller investors via the shortfall offer, which was afloat allocated.

Under the offer, investors were capable to subscribe for 2 caller shares for each 5 held astatine an contented terms of $0.005 per share, on with 1 free-attaching enactment for each 2 caller shares issued.

Those options transportation a two-year word and an workout terms of $0.01, providing imaginable further backing if exercised.

All shortfall securities were placed successful full, reflecting beardown request crossed some retail and caller capitalist cohorts. Blue Ocean Equities and Cygnet Capital acted arsenic associated pb managers to the transaction.

New shares are expected to statesman trading connected a mean colony ground from April 16, ranking arsenic with existing shares.

The rise comes arsenic Percheron builds momentum down HMBD-002, its monoclonal antibody targeting the immune checkpoint regulator VISTA — an emerging absorption successful next-generation crab immunotherapy.

The therapy has already completed a signifier I proceedings successful patients with precocious cancers, wherever it was shown to beryllium mostly harmless and good tolerated, and the institution is present moving towards initiating a signifier II survey successful 2026 to further measure efficacy.

Near-term catalysts are besides coming into focus. Percheron is acceptable to contiguous signifier I information astatine the American Association for Cancer Research yearly gathering this month, followed by caller preclinical results from its collaboration with QIMR Berghofer astatine the American Society of Clinical Oncology gathering successful May–June.

Together, these updates signifier portion of a broader propulsion to validate HMBD-002 wrong the planetary oncology community, peculiarly arsenic involvement grows successful immune checkpoint targets beyond established PD-1 and CTLA-4 pathways.

With caller superior secured and a dependable watercourse of information expected, Percheron is positioning its pb plus for the modulation into mid-stage objective development.